Clene Inc Stock Today
| CLNN Stock | USD 5.82 0.07 1.22% |
Performance0 of 100
| Odds Of DistressOver 82
|
Clene is selling at 5.82 as of the 11th of September 2024; that is 1.22% up since the beginning of the trading day. The stock's open price was 5.75. Clene has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Clene Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of August 2024 and ending today, the 11th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of December 2020 | Category Consumer Defensive | Classification Health Care |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company has 6.47 M outstanding shares of which 158.08 K shares are currently shorted by private and institutional investors with about 0.73 trading days to cover. More on Clene Inc
Moving against Clene Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Clene Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Robert MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Consumer Defensive, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsClene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Clene's financial leverage. It provides some insight into what part of Clene's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clene Inc (CLNN) is traded on NASDAQ Exchange in USA. It is located in 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121 and employs 82 people. Clene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.2 M. Clene Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.47 M outstanding shares of which 158.08 K shares are currently shorted by private and institutional investors with about 0.73 trading days to cover.
Clene Inc currently holds about 16.23 M in cash with (30.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Check Clene Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Clene Inc is $37.2 Million. Clene Inc retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Clene Ownership Details
Clene Historical Income Statement
Clene Stock Against Markets
Clene Corporate Management
| Robert MD | Chief Officer | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Tae Mgt | Consultant | Profile | |
| Mark ESQ | Chief Officer | Profile | |
| Michael Hotchkin | Chief Officer | Profile | |
| Mark Mortenson | CoFounder Officer | Profile |
Additional Information and Resources on Investing in Clene Stock
When determining whether Clene Inc is a strong investment it is important to analyze Clene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clene's future performance. For an informed investment choice regarding Clene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clene Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.614 | Earnings Share (3.07) | Revenue Per Share 0.069 | Quarterly Revenue Growth (0.66) | Return On Assets (0.42) |
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.